SCHEMBL22971737

SCHEMBL22971737

N#Cc1cccc(-c2csc(NC(=O)CNC(=O)c3ccc(N)cc3)n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A2 P19784 1/20 0.53
▸ CSNK2B P67870 1/20 0.53
▸ CSNK2A1 P68400 1/20 0.53
▸ CSNK2A3 Q8NEV1 1/20 0.53
▸ ROCK2 O75116 1/20 0.50
▸ HDAC3 O15379 6/20 0.48
▸ HDAC1 Q13547 6/20 0.48
▸ HDAC2 Q92769 6/20 0.48
▸ HDAC10 Q969S8 6/20 0.48
▸ HDAC6 Q9UBN7 4/20 0.48
▸ HDAC8 Q9BY41 3/20 0.48
▸ HDAC4 P56524 2/20 0.48
▸ HDAC7 Q8WUI4 2/20 0.48
▸ HDAC11 Q96DB2 2/20 0.48
▸ HDAC9 Q9UKV0 2/20 0.48
▸ HDAC5 Q9UQL6 2/20 0.48
▸ ALK Q9UM73 5/20 0.46
▸ NCOR2 Q9Y618 1/20 0.46
▸ ROCK1 Q13464 2/20 0.45
▸ CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22971732 0.98 CSNK2A2 (0.51) CSNK2A2CSNK2BCSNK2A1CSNK2A3ROCK2
SCHEMBL22971734 0.92 KDM4E (0.48) CSNK2A2CSNK2BCSNK2A1CSNK2A3ROCK2
SCHEMBL22290274 0.85 CSNK2A2 (0.54) CSNK2A2CSNK2BCSNK2A1CSNK2A3ROCK2
SCHEMBL21241928 0.85 SCD (0.60) HDAC3HDAC1HDAC2HDAC10HDAC6
SCHEMBL22971635 0.85 ROCK1 (0.56) ROCK2HDAC3HDAC1HDAC2HDAC10
SCHEMBL21241936 0.85 HDAC3 (0.50) CSNK2A2CSNK2BCSNK2A1CSNK2A3HDAC3
SCHEMBL22971654 0.85 ABL1 (0.55) ROCK2HDAC3HDAC1HDAC2HDAC10
SCHEMBL22971735 0.84 HDAC1 (0.56) ROCK2HDAC3HDAC1HDAC2HDAC10
SCHEMBL22971678 0.84 HDAC3 (0.49) HDAC3HDAC1HDAC2HDAC10HDAC6
SCHEMBL23704858 0.83 CSNK2A2 (0.47) CSNK2A2CSNK2BCSNK2A1CSNK2A3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 — — US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 — — US disclosed
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 — — US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CSNK2A2 716/4885CSNK2B 868/4885CSNK2A1 942/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CSNK2A2 716/4885CSNK2B 868/4885CSNK2A1 942/4885
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 CSNK2A2 649/4885CSNK2B 611/4885CSNK2A1 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback